About this trial
Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality.
The study aim is to investigate the role of the protein convertase subtilisin/kexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses:
1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls 2. The level of PCSK9 in plasma correlates to the degree of proteinuria. 3. PCSK9 i increased in the kidney tissue of patients with NS
The study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.
Eligibility criteria
Qualifiers
18 years old
Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus.
Disqualifiers
Refusal to give informed consent
Treatment with PCSK9 inhibitors
Any acute or chronic condition that would limit the ability of the patient to participate in the study
Control group: proteinuria
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Locations
1Sponsors and collaborators
Kolding Sygehus
Lead sponsor
Odense University Hospital
Collaborator
Vejle Hospital
Collaborator